CN111132687A - 兴奋性神经毒性相关损伤的治疗肽组合物 - Google Patents

兴奋性神经毒性相关损伤的治疗肽组合物 Download PDF

Info

Publication number
CN111132687A
CN111132687A CN201780095182.7A CN201780095182A CN111132687A CN 111132687 A CN111132687 A CN 111132687A CN 201780095182 A CN201780095182 A CN 201780095182A CN 111132687 A CN111132687 A CN 111132687A
Authority
CN
China
Prior art keywords
pharmaceutical composition
peptide
injury
buffer
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780095182.7A
Other languages
English (en)
Other versions
CN111132687B (zh
Inventor
韩化敏
田雨佳
贾红军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocells Beijing Biotech Co Ltd
Original Assignee
Biocells Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocells Beijing Biotech Co Ltd filed Critical Biocells Beijing Biotech Co Ltd
Publication of CN111132687A publication Critical patent/CN111132687A/zh
Application granted granted Critical
Publication of CN111132687B publication Critical patent/CN111132687B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本申请提供了包括药物组合物，其包含含氨基酸序列YEKLLDTEI(SEQ ID NO:1)或其功能性变体的肽、pH调节剂和填充剂，所述肽为治疗中枢神经***损伤的活性肽。本申请还提供了药物组合物，其包括嵌合肽、pH调节剂和填充剂，所述嵌合肽包含活性肽和内化肽。本申请还提供了包含活性肽或嵌合肽的药物组合物的医学应用。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201780095182.7A 2017-09-30 2017-09-30 兴奋性神经毒性相关损伤的治疗肽组合物 Active CN111132687B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/104751 WO2019061395A1 (zh) 2017-09-30 2017-09-30 兴奋性神经毒性相关损伤的治疗肽组合物

Publications (2)

Publication Number Publication Date
CN111132687A true CN111132687A (zh) 2020-05-08
CN111132687B CN111132687B (zh) 2023-05-02

Family

ID=65900213

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780095182.7A Active CN111132687B (zh) 2017-09-30 2017-09-30 兴奋性神经毒性相关损伤的治疗肽组合物

Country Status (10)

Country Link
US (1) US11541098B2 (zh)
EP (1) EP3693001A4 (zh)
JP (1) JP7073486B2 (zh)
KR (1) KR102545825B1 (zh)
CN (1) CN111132687B (zh)
AU (1) AU2017433643B2 (zh)
BR (1) BR112020006321A2 (zh)
EA (1) EA202090802A1 (zh)
WO (1) WO2019061395A1 (zh)
ZA (1) ZA202002329B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107913395B (zh) * 2016-10-10 2019-12-13 拜西欧斯（北京）生物技术有限公司 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
AU2021236811A1 (en) * 2020-03-20 2022-10-27 Techfields Inc. Method for improving the stability of a pharmaceutical composition comprising a high penetration drug, and the pharmaceutical composition obtained therefrom

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827604A (zh) * 2007-07-03 2010-09-08 诺诺公司 焦虑治疗
WO2012176172A2 (en) * 2011-06-24 2012-12-27 Nono, Inc. Combination therapy for ischemia
CN110799522A (zh) * 2017-07-05 2020-02-14 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
CN110809579A (zh) * 2017-07-05 2020-02-18 拜西欧斯（北京）生物技术有限公司 多肽的药学可接受的盐及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019841A1 (en) 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CN101134780A (zh) 2007-07-09 2008-03-05 南京医科大学 阻断nr2b信号通路的多肽类似物及其制备方法和药物用途
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
AU2009288088B2 (en) 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
WO2010129469A1 (en) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
WO2012156308A1 (en) 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
CN103159832B (zh) * 2011-12-08 2014-11-12 徐州医学院 具有神经保护作用的肽及其制备方法、药物组合物和用途
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2016140527A1 (ko) * 2015-03-04 2016-09-09 경상대학교산학협력단 오스모틴 펩티드를 유효성분으로 함유하는 신경질환의 예방, 개선 또는 치료용 조성물
WO2017185249A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
CN109718363B (zh) 2017-10-26 2019-12-13 拜西欧斯（北京）生物技术有限公司 预防、缓解或治疗阿尔茨海默病的肽及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827604A (zh) * 2007-07-03 2010-09-08 诺诺公司 焦虑治疗
WO2012176172A2 (en) * 2011-06-24 2012-12-27 Nono, Inc. Combination therapy for ischemia
CN103648518A (zh) * 2011-06-24 2014-03-19 诺诺公司 局部缺血的组合治疗
CN110799522A (zh) * 2017-07-05 2020-02-14 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
CN110809579A (zh) * 2017-07-05 2020-02-18 拜西欧斯（北京）生物技术有限公司 多肽的药学可接受的盐及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUCIANA CATANESE ET AL.: "Acute Ischemic Stroke Therapy Overview", 《CIRC RES.》 *
P J LOLL等: "Active site mutant Glu-43---Asp in staphylococcal nuclease displays nonlocal structural changes", 《BIOCHEMISTRY》 *

Also Published As

Publication number Publication date
EP3693001A4 (en) 2021-07-07
JP7073486B2 (ja) 2022-05-23
JP2020536065A (ja) 2020-12-10
EP3693001A1 (en) 2020-08-12
KR20200066334A (ko) 2020-06-09
BR112020006321A2 (pt) 2020-11-17
ZA202002329B (en) 2022-12-21
US11541098B2 (en) 2023-01-03
WO2019061395A1 (zh) 2019-04-04
US20210000909A1 (en) 2021-01-07
EA202090802A1 (ru) 2020-08-05
CN111132687B (zh) 2023-05-02
AU2017433643A1 (en) 2020-05-14
AU2017433643B2 (en) 2022-04-28
KR102545825B1 (ko) 2023-06-22

Similar Documents

Publication Publication Date Title
CN107312069B (zh) 兴奋性神经毒性相关损伤的治疗肽
CN110799522B (zh) 用于治疗、改善或预防脑出血的肽及其用途
CN110799547B (zh) 用于治疗、改善或预防神经***相关病症的化合物及其用途
CN111132687B (zh) 兴奋性神经毒性相关损伤的治疗肽组合物
CN110809579B (zh) 多肽的药学可接受的盐及其应用
KR102253900B1 (ko) 흥분성 신경독성 관련 손상 치료용 펩타이드
CN107312071B (zh) 兴奋性神经毒性相关损伤的治疗方法
EA044400B1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
WO2017185250A1 (zh) 兴奋性神经毒性相关损伤的治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant